SS Innovations International Inc. (NASDAQ: SSII) has brought robotic cardiac surgery to Sri Lanka with the launch of the country's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the SSi Mantra 3.0 surgical robotic system and began with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video.
The introduction of robotic cardiac surgery in Sri Lanka represents a significant advancement for the country's healthcare sector. Robotic-assisted procedures offer the potential for smaller incisions, reduced blood loss, faster recovery times, and improved patient outcomes compared to traditional open-heart surgery. By bringing this technology to Sri Lanka, SS Innovations is not only expanding its global footprint but also addressing the need for advanced surgical options in emerging markets. Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and the system's usability.
This launch is part of SS Innovations' broader strategy to penetrate international markets and drive adoption of its SSi Mantra system. As of the end of the second quarter, the company reported 224 cumulative SSi Mantra installations across 12 countries. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, indicating rising utilization of the installed base. This growth trajectory suggests that the company's efforts to expand into new geographies are yielding tangible results.
The next major milestone for SS Innovations is regulatory expansion, as the company pursues U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to two of the largest healthcare markets in the world, potentially accelerating revenue growth and solidifying the company's position in the global surgical robotics industry. The successful implementation in Sri Lanka serves as a proof point for the system's capabilities and could bolster the company's case with regulators.
For investors, this news matters because it demonstrates SS Innovations' ability to execute on its international expansion plans and drive adoption in new markets. The rapid uptake of robotic procedures at Kings Hospital suggests that the SSi Mantra system is well-received by surgeons and healthcare providers. Moreover, the company's strong procedure growth and installation numbers indicate increasing market penetration, which could lead to recurring revenue streams from consumables and services. As SS Innovations works toward FDA and CE mark approvals, the potential for further market expansion and revenue growth is substantial.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
